Background: Negative lymph node (NLN) count has been validated as a protective predictor in various cancers after radical resection. However, the prognostic value of NLN count in the setting of gastric cancer patients who have received palliative resection has not been investigated. The aim of the present study was to explore the effect of NLN counts on the survival outcomes in patients with stage IV gastric cancer after palliative resection. Methods: Surveillance, Epidemiology, and End Results Program (SEER)-registered gastric cancer patients were used for analysis in this study. Kaplan-Meier survival curves and multivariate Cox proportional hazards model were used to assess the risk factors for survival. Results: A total of 1,495 patients with stage IV gastric cancer underwent palliative resection were identified from SEER database between 2004 and 2011. It showed that NLN count (P < 0.001) and N stage (P < 0.001) were independently prognostic factors in patients with stage IV gastric cancer after palliative surgery. X-tile plots identified 2 and 11 as the optimal cutoff values to divide the patients into high, middle and low risk subsets in term of cause-specific survival (CSS). And NLN count was proved to be an independently prognostic factor in multivariate Cox analysis (2-10, HR ¼ 0.762, 95% CI: 0.660-0.880, 11, HR ¼ 0.525, 95% CI: 0.437-0.632, P<0.001, 0-1 as reference). The risk score of NLN counts demonstrated that the plot of hazard ratios (HRs) for NLN counts sharply increased when the number of NLN counts decreased. Conclusions: Our present study revealed that NLN count was an independent prognostic predictor in stage IV gastric cancer after palliative resection. Standard lymph node dissection, such as D2 lymphadectomy maybe still necessary during palliative resection for patients with metastatic gastric cancer. Legal entity responsible for the study: N/A Funding: None Disclosure: All authors have declared no conflicts of interest.
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Results: There was a significant correlation between TC and IC PD-L1 expression in primary tumours (p < 0.001) but not in metastases. There was no significant association between TC PD-L1 expression in primary tumours and metastases, but IC PD-L1 expression was significantly higher in metastases (p ¼ 0.027).There were strong significant associations between PD-L1 expression in TC and IC, respectively, and MSI (p < 0.001 for both). Neither TC PD-L1 expression nor MSI status was prognostic. However, high IC PD-L1 expression (>50%) was significantly associated with a prolonged OS, independent of conventional prognostic factors and MSI status (HR ¼ 0.39, 95% CI 0.15-0.99). Conclusions: PD-L1 expression in TC does not differ significantly between primary tumours and lymph node metastases, PD-L1 expression in IC but not in TC is an independent favourable prognostic factor. Legal entity responsible for the study: Lund University Funding: This study was supported by grants from the Swedish Cancer Society, the Swedish Research Council, the Mrs. Berta Kamprad Foundation, the Swedish Government 
